加勒比免疫技术咨询组(CITAG):独特的国家免疫技术咨询组模式
本文介绍2018年启动的加勒比免疫技术咨询组(CITAG),该区域22个国家/地区因技术专长有限难以各自建立国家免疫技术咨询组(NITAG)。文章回顾区域免疫挑战与解决方案,指出免疫率下降及全球疫苗可预防疾病暴发使作为旅游目的地的加勒比地区处于脆弱状态,CITAG旨在加强免疫政策与循证决策。
要点
- 加勒比22个国家/地区因技术专长有限,难以各自建立NITAG。
- CITAG于2018年启动,作为区域共同框架支持免疫循证决策。
- 区域免疫率下降叠加全球疫苗可预防疾病暴发,增加脆弱性。
核心结论
- CITAG旨在加强免疫政策与循证决策,使加勒比地区保持疫苗可预防疾病消除的前沿地位。
研究设计与样本
- 本文为描述性文章,介绍加勒比地区免疫政策与循证决策共同框架的背景及CITAG。
主要发现
- 加勒比地区近期免疫率下降,全球疫苗可预防疾病暴发使该旅游目的地处于脆弱状态。
临床怎么用
- CITAG可作为区域共同框架,支持小国家开展免疫政策与循证决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Global Vaccine Action Plan 2011-2020 called for all countries to establish a National Immunization Technical Advisory Group (NITAG) by 2020. The Caribbean, with its unique geographical context of 22 countries/territories, had limited technical expertise to establish individual NITAGs in small countries. The Caribbean Immunization Technical Advisory Group (CITAG) was launched in 2018. This paper describes the Caribbean context for a common framework for policy and evidence-based decision-making for immunization. Challenges in immunization in the region are reviewed and potential solutions are outlined. A recent decline in immunization rates in the Caribbean, along with outbreaks of vaccine-preventable diseases globally, places the region, a premier tourist destination, in a vulnerable position. The CITAG aims to strengthen the policy and evidence-based decision-making process for immunization to enable the Caribbean to remain at the forefront of vaccine-preventable disease elimination.
引用
- Evans-Gilbert T, Lewis-Bell KN, Figueroa JP, et al. The Caribbean Immunization Technical Advisory Group (CITAG); A unique NITAG. Vaccine. 2019. PMID: 31537448. doi:10.1016/j.vaccine.2019.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。